Background: The nicotinic acetylcholine receptor (nAChR) subunit alpha-9 (CHRNA9) is a unique cholinergic receptor, which is involved in tumor proliferation, apoptosis, metastasis and chemotherapy resistance. However, the correlation between the expression level of CHRNA9 in glioma and the clinical features and prognosis of glioma patients has not been clarified. The aim of this study was to verify the expression level of CHRNA9 in glioma and its effect on prognosis by bioinformatics methods./nMethods: The RNA-seq data of glioma and normal samples were obtained from the TCGA and GTEx databases. Bioinformatics methods were utilized to analyze the differential expression of CHRNA9 between tumor samples and normal samples. The potential association between CHRNA9 and the clinicopathological features of glioma patients was also investigated. The Kaplan-Meier method and Cox regression were utilized to analyze the relationship between CHRNA9 expression level and survival time and prognostic value of glioma patients. Enrichment analysis was applied to predict gene function and signaling pathways associated with CHRNA9. Experimental verification was performed using tumor tissues and paracancerous tissues from glioma patients./nResults: The results of bioinformatics analysis showed that the expression of CHRNA9 was increased in glioma tissues, correlating with poor prognosis and reduced patient survival time. Enrichment analysis suggested that CHRNA9 may interact with the JAK/STAT pathway. CHRNA9 was also found to be abnormally expressed in various other tumors and associated with the expression levels of numerous immune checkpoints in glioma. The findings from the analysis of clinical samples revealed that the expression levels of both mRNA and protein of CHRNA9 in glioma tissues were higher than those in paracancerous tissues. Similarly, the mRNA expression levels of STAT3, IL-6, and TNF-α, which are crucial factors in the STAT3 pathway, were elevated in glioma tissues compared to paracancerous tissues./nConclusion: CHRNA9 is a potential prognostic marker and immunotherapy target for glioma, with its mechanism of action potentially linked to the STAT3 pathway.

中文翻译：

---

CHRNA9 作为神经胶质瘤的新预后标志物和潜在治疗靶点

背景：烟碱型乙酰胆碱受体（nAChR）亚基α-9（CHRNA9）是一种独特的胆碱能受体，参与肿瘤增殖、凋亡、转移和化疗耐药。然而，胶质瘤中CHRNA9的表达水平与胶质瘤患者的临床特征和预后之间的相关性尚未明确。本研究的目的是通过生物信息学方法验证CHRNA9在胶质瘤中的表达水平及其对预后的影响。/n方法：从TCGA和GTEx数据库获得胶质瘤和正常样本的RNA-seq数据。利用生物信息学方法分析肿瘤样本与正常样本之间CHRNA9的差异表达。还研究了 CHRNA9 与神经胶质瘤患者的临床病理特征之间的潜在关联。采用Kaplan-Meier法和Cox回归分析CHRNA9表达水平与胶质瘤患者生存时间和预后价值的关系。应用富集分析来预测与 CHRNA9 相关的基因功能和信号通路。使用胶质瘤患者的肿瘤组织和癌旁组织进行实验验证。/n结果：生物信息学分析结果显示，胶质瘤组织中CHRNA9表达升高，与预后不良、患者生存时间缩短相关。富集分析表明 CHRNA9 可能与 JAK/STAT 通路相互作用。CHRNA9 还被发现在多种其他肿瘤中异常表达，并与神经胶质瘤中众多免疫检查点的表达水平相关。临床样本分析结果显示，胶质瘤组织中CHRNA9 mRNA和蛋白的表达水平均高于癌旁组织。同样，与癌旁组织相比，STAT3、IL-6 和 TNF-α（STAT3 通路中的关键因子）的 mRNA 表达水平在胶质瘤组织中升高。/n结论： CHRNA9 是潜在的预后标志物和免疫治疗靶点对于神经胶质瘤，其作用机制可能与 STAT3 通路相关。